The online version of this article (doi:10.1186/1471-2407-14-106) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
FM is the PI of the EPICAP study. She conceived the study, designed the protocol and is in charge of the overall coordination of the study. She wrote the manuscript. AA has been the study monitor for the first 18 months and HR is the current study monitor of the EPICAP study. CM and PLP are in charge of the biological samples (EDTA tubes for cases and controls). FI, BL and RT are the referent urologist in the different health care department. They federated all urologists who work with them in their department. BL (urologist) is in charge of medical/histological validation of the cases in the different health care department. PJL is in charge of the biological samples (dry tubes for cases and controls) and is responsible for the “prognostic part” of the study. XR (urologist) and BT (head of the Hérault Cancer Registry) are part of the steering committee which meets every 3-4 months. All authors read and approved the final manuscript.
Prostate cancer is the most common cancer in male in most Western countries, including France. Despite a significant morbidity and mortality to a lesser extent, the etiology of prostate cancer remains largely unknown. Indeed, the only well-established risk factors to date are age, ethnicity and a family history of prostate cancer. We present, here, the rationale and design of the EPIdemiological study of Prostate CAncer (EPICAP), a population-based case–control study specifically designed to investigate the role of environmental and genetic factors in prostate cancer. The EPICAP study will particularly focused on the role of circadian disruption, chronic inflammation, hormonal and metabolic factors in the occurrence of prostate cancer.
EPICAP is a population-based case–control study conducted in the département of Hérault in France. Eligible cases are all cases of prostate cancers newly diagnosed in 2012-2013 in men less than 75 years old and residing in the département of Hérault at the time of diagnosis. Controls are men of the same age as the cases and living in the département of Hérault, recruited in the general population.
The sample will include a total of 1000 incident cases of prostate cancer and 1000 population-based controls over a 3-year period (2012-2014).
The cases and controls are face-to-face interviewed using a standardized computed assisted questionnaire. The questions focus primarily on usual socio-demographic characteristics, personal and family medical history, lifestyle, leisure activities, residential and occupational history. Anthropometric measures and biological samples are also collected for cases and controls.
The EPICAP study aims to answer key questions in prostate cancer etiology: (1) role of circadian disruption through the study of working hours, chronotype and duration/quality of sleep, (2) role of chronic inflammation and anti-inflammatory drugs, (3) role of hormonal and metabolic factors through a detailed questionnaire, (4) role of individual genetic susceptibility of genes involved in biological pathways of interest. The EPICAP study will also allow us to study prognostic factors and tumor aggressiveness.
Taken together, the EPICAP study will provide a comprehensive framework to go further in the understanding of prostate cancer occurrence and its prognosis.
Additional file 1: English summarized version of the EPICAP questionnaire.(DOCX 12 KB)12885_2013_4333_MOESM1_ESM.docx
InVS: Projections de l’incidence et de la mortalité par cancer en France en 2011. Rapport technique. 2011, Saint-Maurice: Institut de veille sanitaire
Hsing AW, Sakoda LC, Chua S: Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007, 86: s843-s857. PubMed
Lee J, Demissie K, Lu S-E, Rhoads GG: Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control. 2007, 14: 78-85. PubMed
Stevens RG, Hansen J, Costa G, Haus E, Kauppinen T, Aronson KJ, Castaño-Vinyals G, Davis S, Frings-Dresen MHW, Fritschi L, Kogevinas M, Kogi K, Lie J-A, Lowden A, Peplonska B, Pesch B, Pukkala E, Schernhammer E, Travis RC, Vermeulen R, Zheng T, Cogliano V, Straif K: Considerations of circadian impact for defining “shift work” in cancer studies: IARC Working Group Report. Occup Environ Med. 2011, 68: 154-162. 10.1136/oem.2009.053512. CrossRefPubMed
Sigurdardottir LG, Valdimarsdottir UA, Fall K, Rider JR, Lockley SW, Schernhammer E, Mucci LA: Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2012, 21: 1002-1011. 10.1158/1055-9965.EPI-12-0116. CrossRefPubMedPubMedCentral
Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, Miki T, Nakao M, Hayashi K, Suzuki K, Mori M, Washio M, Sakauchi F, Ito Y, Yoshimura T, Tamakoshi A: Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol. 2006, 164: 549-555. 10.1093/aje/kwj232. CrossRefPubMed
Conlon M, Lightfoot N, Kreiger N: Rotating shift work and risk of prostate cancer. Epidemiol. 2007, 18: 182-183. 10.1097/01.ede.0000249519.33978.31. CrossRef
Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, et al: Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 2002, 30: 181-184. 10.1038/ng823. CrossRefPubMed
Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M: Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009, 10: 501-507. 10.1016/S1470-2045(09)70035-X. CrossRefPubMed
Nomura AM, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk FZ: Serum androgens and prostate cancer. Cancer Epidemiol Biomark Prev. 1996, 5: 621-625.
Hsing AW, Chu LW, Stanczyk FZ: Androgen and prostate cancer: is the hypothesis dead?. Cancer Epidemiol Biomark Prev. 2008, 17: 2525-2530. 10.1158/1055-9965.EPI-08-0448. CrossRef
Wigle DT, Turner MC, Gomes J, Parent M-E: Role of hormonal and other factors in human prostate cancer. Eur J Toxicol Environ Health Part B, Crit Rev. 2008, 11: 242-259. 10.1080/10937400701873548. CrossRef
Jacobs EJ, Gapstur SM: Cholesterol and cancer: answers and new questions. Cancer Epidemiol Biomark Prev. 2009, 18: 2805-2806. 10.1158/1055-9965.EPI-09-1027. CrossRef
Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM, Kristal AR: Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev. 2009, 18: 2807-2813. 10.1158/1055-9965.EPI-09-0472. CrossRef
Rebbeck TR: Inherited genotype and prostate cancer outcomes. Cancer Epidemiol Biomark Prev. 2002, 11 (10 Pt 1): 945-952.
Rybicki BA, Ph D, Neslund-dudas C, Nock NL, Schultz LR, Eklund L, Rosbolt J, Bock CH, Monaghan KG: Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism. Cancer Detect Prev. 2006, 30 (5): 412-422. 10.1016/j.cdp.2006.09.004. CrossRefPubMedPubMedCentral
Zhu Y, Zheng T, Stevens RG, Zhang Y, Boyle P: Does “clock” matter in prostate cancer?. Cancer Epidemiol Biomark Prev. 2006, 15: 3-5. 10.1158/1055-9965.EPI-05-0631. CrossRef
Chu LW, Zhu Y, Yu K, Zheng T, Chokkalingam AP, Stanczyk FZ, Gao Y-T, Hsing AW: Correlation between circadian gene variants and serum levels of sex steroids and insulin-like growth factor-I. Cancer Epidemiol Biomark Prev. 2008, 17: 3268-3273. 10.1158/1055-9965.EPI-08-0073. CrossRef
Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, Van der Kwast T, Kujala PM, Blijenberg BG, Stenman U-H, Huber A, Taari K, Hakama M, Moss SM, De Koning HJ, Auvinen A: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012, 366: 981-990. 10.1056/NEJMoa1113135. CrossRefPubMed
European Foundation for the Improvement of living and Working Conditions: Fourth European Working Conditions Survey. 2007, Luxembourg: Office for Official Publications of the European Communities
- Epidemiological study of prostate cancer (EPICAP): a population-based case–control study in France
EPICAP Study Group
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II